This is in contrast to the given medical treatment and growing use of newer anti-glycemic treatments, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) agonists in patients with overt DM. This evidence concerns the gene GCG and diabetes mellitus.